Sierra Oncology Inc (SRRA) gains 0.51% for July 21

Equities Staff  |

Sierra Oncology Inc (NASDAQ: SRRA) shares gained 0.51%, or $0.1 per share, to close Wednesday at $19.90. After opening the day at $19.80, shares of Sierra Oncology fluctuated between $20.34 and $19.80. 12,208 shares traded hands a decrease from their 30 day average of 27,795. Wednesday's activity brought Sierra Oncology’s market cap to $245,764,224.

Sierra Oncology is headquartered in Vancouver, British Columbia..

About Sierra Oncology Inc

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Visit Sierra Oncology Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Sierra Oncology Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Sierra Oncology Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Market Movers

Sponsored Financial Content